Advanced Cell Technology, Inc. (OTCBB: ACTC), a leader in the field of regenerative medicine, announced today the dosing of an additional patient in its Phase 1/2 trial for Stargardt’s macular dystrophy using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
The patient was treated on Tuesday (Jan. 24) by Steven Schwartz, M.D., Ahmanson Professor of ...
Continue Reading →JAN